Phreesia, Inc. (NYSE:PHR) Receives Average Recommendation of “Moderate Buy” from Analysts

Phreesia, Inc. (NYSE:PHR) has earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $29.42.

A number of brokerages have issued reports on PHR. Canaccord Genuity Group restated a “buy” rating and set a $34.00 target price on shares of Phreesia in a report on Thursday, September 5th. Royal Bank of Canada reissued a “sector perform” rating and issued a $23.00 price target on shares of Phreesia in a report on Friday, September 27th. DA Davidson reaffirmed a “buy” rating and set a $32.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Robert W. Baird boosted their target price on Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. Finally, Truist Financial increased their price target on Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, September 6th.

Phreesia Trading Up 1.0 %

Phreesia stock opened at $18.47 on Friday. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -10.26 and a beta of 0.93. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. Phreesia has a 12 month low of $14.17 and a 12 month high of $29.16. The business has a 50 day moving average price of $22.19 and a two-hundred day moving average price of $22.11.

Phreesia (NYSE:PHR) last issued its earnings results on Wednesday, September 4th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The company had revenue of $102.12 million for the quarter, compared to the consensus estimate of $101.76 million. As a group, equities analysts forecast that Phreesia will post -1.23 EPS for the current year.

Insiders Place Their Bets

In other Phreesia news, SVP David Linetsky sold 1,716 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total value of $39,897.00. Following the transaction, the senior vice president now directly owns 203,318 shares of the company’s stock, valued at $4,727,143.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Phreesia news, SVP David Linetsky sold 1,716 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $39,897.00. Following the transaction, the senior vice president now directly owns 203,318 shares of the company’s stock, valued at $4,727,143.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, General Counsel Allison C. Hoffman sold 14,110 shares of Phreesia stock in a transaction on Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the sale, the general counsel now directly owns 121,003 shares of the company’s stock, valued at $3,149,708.09. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,107 shares of company stock valued at $1,035,226 over the last ninety days. 5.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Phreesia by 4.4% in the fourth quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock valued at $107,148,000 after buying an additional 194,035 shares in the last quarter. Champlain Investment Partners LLC purchased a new position in Phreesia during the first quarter worth about $29,941,000. Boston Partners bought a new stake in Phreesia during the first quarter worth $669,000. Blair William & Co. IL grew its position in shares of Phreesia by 42.6% during the 1st quarter. Blair William & Co. IL now owns 752,700 shares of the company’s stock valued at $18,012,000 after acquiring an additional 224,950 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Phreesia by 1,407.9% during the 1st quarter. Russell Investments Group Ltd. now owns 57,874 shares of the company’s stock valued at $1,385,000 after buying an additional 54,036 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.